sufentanil sublingual tablet 30 mcg
Phase 3Completed 1 views this week 0 watching💤 Quiet
Interest: 30/100
30
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Acute Moderate-to-severe Pain
Conditions
Acute Moderate-to-severe Pain
Trial Timeline
Mar 1, 2016 → Jul 1, 2016
NCT ID
NCT02662556About sufentanil sublingual tablet 30 mcg
sufentanil sublingual tablet 30 mcg is a phase 3 stage product being developed by Talphera for Acute Moderate-to-severe Pain. The current trial status is completed. This product is registered under clinical trial identifier NCT02662556. Target conditions include Acute Moderate-to-severe Pain.
What happened to similar drugs?
20 of 20 similar drugs in Acute Moderate-to-severe Pain were approved
Approved (20) Terminated (4) Active (0)
✅Modification of Prasugrel based on a biological assay + prasugrel / clopidogrelDaiichi SankyoApproved
Hype Score Breakdown
Clinical
17
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02662556 | Phase 3 | Completed |
Competing Products
20 competing products in Acute Moderate-to-severe Pain